Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorVázquez Varela, Miriam
dc.contributor.authorAltabas González, Manuel
dc.contributor.authorMoreno, Diana C
dc.contributor.authorGeng Cahuayme, Abraham Andre Artu
dc.contributor.authorPérez Hoyos, Santiago
dc.contributor.authorGiralt López de Sagredo, Jordi
dc.date.accessioned2021-12-16T07:07:47Z
dc.date.available2021-12-16T07:07:47Z
dc.date.issued2021-04-23
dc.identifier.citationVázquez M, Altabas M, Moreno DC, Geng AA, Pérez-Hoyos S, Giralt J. 30-Day Mortality Following Palliative Radiotherapy. Front Oncol. 2021 Apr;11:668481.
dc.identifier.issn2234-943X
dc.identifier.urihttp://hdl.handle.net/11351/6694
dc.descriptionClinical indicator; Palliative radiation; Prognosis
dc.description.abstractPurpose: 30-day mortality (30-DM) is a parameter with widespread use as an indicator of avoidance of harm used in medicine. Our objective is to determine the 30-DM followed by palliative radiation therapy (RT) in our department and to identify potential prognosis factors. Material/Methods: We conducted a retrospective cohort study including patients treated with palliative RT in our center during 2018 and 2019. Data related to clinical and treatment characteristics were collected. Results: We treated 708 patients to whom 992 palliative irradiations were delivered. The most frequent primary tumor sites were lung (31%), breast (14.8%), and gastrointestinal (14.8%). Bone was the predominant location of the treatment (56%), and the use of single doses was the preferred treatment schedule (34.4%). The 30-DM was 17.5%. For those who died in the first month the median survival was 17 days. Factors with a significant impact on 30-DM were: male gender (p < 0.0001); Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 2–3 (p = 0.0001); visceral metastases (p = 0.0353); lung, gastrointestinal or urinary tract primary tumors (p = 0.016); and single dose RT (p = <0.0001). In the multivariate analysis, male gender, ECOG PS 2–3, gastrointestinal and lung cancer were found to be independent factors related to 30-DM. Conclusion: Our 30-DM is similar to previous studies. We have found four clinical factors related to 30-DM of which ECOG was the most strongly associated. This data may help to identify terminally ill patients with poor prognosis in order to avoid unnecessary treatments.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Radioteràpia
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectCàncer - Tractament pal·liatiu
dc.subject.meshNeoplasms
dc.subject.mesh/radiotherapy
dc.subject.meshTreatment Outcome
dc.subject.meshPalliative Care
dc.title30-Day Mortality Following Palliative Radiotherapy
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fonc.2021.668481
dc.subject.decsneoplasias
dc.subject.decs/radioterapia
dc.subject.decsresultado del tratamiento
dc.subject.decscuidados paliativos
dc.relation.publishversionhttps://doi.org/10.3389/fonc.2021.668481
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Vázquez M, Altabas M, Moreno DC, Geng AA, Giralt J] Servei d’Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pérez-Hoyos S] Unitat d'Estadística i Bioinformàtica, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid33968775
dc.identifier.wos000648029700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record